Clinical Trial Update: Apixaban for Primary Prevention of Venous Thromboembolism in Patients With Multiple Myeloma [Phase 4]

View source ↗

Summary

Phase 4 trial update on apixaban for primary prevention of venous thromboembolism in patients with multiple myeloma; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma
• Venous Thromboembolism

Drugs mentioned

• Apixaban (apixaban)

Snippet

Sponsor: Gregory Piazza | Conditions: Venous Thromboembolism, Multiple Myeloma | Phase 4 | Status: COMPLETED | Results posted: 2019-12-06